Revenue Contribution: 11%
- Presence in 52 countries including direct to market models in 13 countries
- Strong leadership position across key Emerging markets 1
- Respiratory in Sri Lanka & Nepal
- ARV in Myanmar
- Biosimilars franchise - Australia, New Zealand, Colombia and Malaysia
- Continued leadership position in Respiratory in Sri Lanka
Revenue Contribution: 38%
- Cipla became the 2nd biggest player growing over 18% (Chronic therapies)
- Market leader in Respiratory & Urology 1
Revenue Contribution: 21%
- Launch and ramp-up of differentiated products (gPulmicort, gVoltaren,gIsuprel,gSensipar)
SAGA (South Africa, Sub-Saharan Africa, Global Access)
Revenue contrbution: 20%
- South Africa business grew 3x the market at 10.4% 1 in the private market
- Expanded offering beyond medicines to patients - Acquisition of Brandmed, a connected health solutions company
Revenue Contribution: 4%
- Strong ramp-up in key respiratory products
- Fluticasone Propionate Salmaterol (FPSM) market share ramping-up steadily
For decades, the Indian pharmaceutical industry has been driving better health outcomes for the economy.Cipla’s commitment to high quality standards has made us the most trusted brand among patients and one of the top Indian pharma companies among healthcare professionals. India continues to be one of the most important and focused markets for Cipla. In FY 18-19, Cipla’s overall domestic business contributed to 39% of the global revenues.
Today, Cipla is the 3rd largest pharmaceutical company in India, with product portfolio spanning across various therapeutic areas including Respiratory, Anti-infectives, Cardio-metabolic, Gastro and Urology.Our strong brand equity, product range and unique dosage forms help us stand out in the fiercely competitive Indian pharmaceutical industry environment. Moreover, we are the market leader in Respiratory and Urology and have 22 brands feature among the top 300 brands of IPM.
Cipla USA Inc., the US subsidiary of Cipla Limited, is the first Indian company to be approved by US FDA in 1985. Headquartered in Miami, FL, Cipla USA Inc.has supported the development of more than 170 ANDAs till date. Over last 5 years, Cipla has significantly expanded its portfolio and presence in the world’s largest pharmaceutical market of US. Building further on the commercial front end acquired through InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc, Cipla has remained amongst the top 12 most dispensed companies in the US during FY 18-19.
The North America business today represents 21% of our overall revenues.
Cipla is investing significant resources with a vision to expand its Respiratory franchise in the US market and gain a significant market presence. A strong pipeline of differentiated and complex molecules are part of Cipla’s pipeline that shall continue to drive growth for US.Know More
Cipla is present in almost all countries in the European region with 4 DTMs in Germany, Norway, Spain and the UK. The change in the business model for the European countries, moving from DTM model to a partnership- led B2B model, has improved profitability significantly. From a Therapy standpoint, while respiratory continues to remain a focus area, Oncology and complex injectable will be a part of the differentiated product portfolio strategy in the region.Read More
Emerging Markets region for Cipla comprises of all markets outside of India, North America, South Africa/ Sub-Saharan Africa and Europe but includes North Africa and Australia. Cipla has presence in 52 countries in this region including direct to market models in 13 countries. Cipla has continued to be present in traditionally considered risky geographies to ensure medicines access to patients. Over years, respiratory has been a key business growth driver for Emerging Markets. Cipla continues to be a Respiratory leader in Sri Lanka, Nepal, & Morocco. The Company continues to focus on deepening its presence in Australia through respiratory portfolio and in markets such as China, Brazil & Indonesia through in-house pipeline products and JV partnerships.
South Africa, Sub-Saharan Africa and Cipla Global Access (SAGA)
Cipla Medpro, a 100% subsidiary of Cipla Limited, has a strong presence across various therapeutic categories in South Africa. Cipla is one of the largest pharmaceutical companies in South Africa by volume and third largest by value. Cipla is recognised widely in Africa for the pioneering role it played in ensuring access to HIV/Aids medication with its innovative tripe-combination anti-retroviral (ARV) in 2001. This was available to patients at less than $1 a day – a significant cost saving – thereby allowing access to millions of people living with HIV/Aids and saving millions of lives in Africa alone.
Our manufacturing facility at Durban provides a competitive edge and is the first Pharmaceutical Inspection Convention (PIC) compliant facility in the South Africa. We also have a world-class distribution centre in Cape Town and satellite offices situated throughout the country to house commercial and regulatory functions.Know More
Based in Melbourne, Cipla Australia has a vast pipeline of products that are supplied in Australia as well as US & EU. Millions of Australians have access to a Cipla manufactured product through our community pharmacy partners around Australia. Our state-of-the-art manufacturing facilities are TGA approved as well as being USFDA (USA) and MHRA (UK) approved. Cipla Australia has over 200 registered; formulations;with TGA through partnerships with market leaders and on its own.Know More